BCRX
BioCrystBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
BCRX vs peer average
69/100
BCRX vs. peer average (B vs. C)
Grade spread
B 2 · C 4 · D 4
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
PHVS is the first available peer comparator.
Pharvaris is a direct HAE competitor because BioCryst's 2025 10-K lists deucrictibant as a Phase 3 oral acute and prophylactic program that could compete with ORLADEYO or navenibart. [#10-K-2026-02-26]
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
BCRX
BioCryst
PHVS
Pharvaris
Grade
B
D
Momentum
58
57
Value
65
41
Sentiment
56
-
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Defensive
Grade position vs PHVS
BCRX / PHVS
Grade Position
In line
BCRX vs. peer average (B vs. C)
69/100
Momentum
58
BCRXValue
65
BCRXSentiment
56
-Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs BCRX
PHVS is the first peer returned for this comparison set.